Multicenter phase II study of modified FOLFIRI regimen in the advanced colorectal cancer patient refractory to fluoropyrimidine and oxaliplatin.
- Author:
Wen ZHANG
1
;
Zi-Yi ZHAO
;
Qing WU
;
Jia CHENG
;
Nong XU
;
Chang-Ping WU
;
Jin LI
;
Li-Gong XU
Author Information
- Publication Type:Journal Article
- MeSH: Adult; Aged; Antineoplastic Agents; therapeutic use; Antineoplastic Combined Chemotherapy Protocols; adverse effects; therapeutic use; Camptothecin; adverse effects; analogs & derivatives; therapeutic use; Colonic Neoplasms; drug therapy; pathology; Diarrhea; chemically induced; Female; Fluorouracil; adverse effects; therapeutic use; Humans; Leucovorin; adverse effects; therapeutic use; Male; Middle Aged; Nausea; chemically induced; Neoplasm Staging; Neutropenia; chemically induced; Organoplatinum Compounds; therapeutic use; Prospective Studies; Pyrimidines; therapeutic use; Rectal Neoplasms; drug therapy; pathology; Remission Induction; Treatment Failure
- From: Chinese Journal of Oncology 2006;28(10):788-790
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo evaluate the efficacy and safety of modified FOLFIRI regimen in advanced colorectal cancer (CRC) patients refractory to fluoropyrimidine and oxaliplatin.
METHODSThe modified FOLFIRI regimen consisted of intravenous infusion of irinotecan 180 mg/m2 d1 + LV 200 mg/m2 dl + 5-Fu 400 mg/m2 bolus dl plus 46-hour intravenous infusion of 5-Fu 2.4 g/m2, every 2 weeks as one cycle. The main selection criterion for this study was the advanced CRC refractory to fluoropyrimidine and oxaliplatin.
RESULTSOf the 80 evaluable patients for efficacy: 10 (12.5%) had a partial response, 51 (63.7%) stable disease, and 19 (23.8%) progressive disease. The median time to progression was 96 days. Safety analysis was based on the data of 83 evaluable patients. The most frequently observed grade 3 or 4 toxicities were neutropenia (24.1%), nausea/vomiting (8.4%), and diarrhea (2.4%).
CONCLUSIONModified FOLFIRI regimen is effective and well tolerated in patients with advanced colorectal cancer refractory to fluoropyrimidine and oxaliplatin.
